Biocytogen to Deliver 1 Oral and 3 Poster Presentations at PEGS EUROPE 2022, Introducing RenLite Platform, TCR-mimic Platform, and Antibody Assets
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced today that the company will present at the upcoming Protein & Antibody Engineering Summit (PEGS EUROPE) conference in Barcelona, Spain on November 14-16, 2022.
- Frank An, Ph.D., Senior Director of Antibody Therapeutics at Biocytogen, will give an oral presentation at 13:50-14:20 on Tuesday, November 15, introducing Biocytogen’s proprietary fully human common light chain antibody platform (RenLite®) and its applications for correct heavy chain and light chain pairing during development of bispecific antibodies (BsAbs) and bispecific antibody-drug conjugates (BsADCs).
In addition, Biocytogen will present 3 posters introducing the latest progress of YH013 (EGFR x MET BsADC), 1C3 (anti-TNFR2 monoclonal antibody), and Biocytogen’s TCR-mimic antibody platform.
Details of our presentations are as follows:
Monday, November 14:
Poster A5：1C3, a Differentiated Non-Blocking Agonist TNFR2 Antibody for Cancer Immunotherapy
Poster A6：A Novel TCR-mimic Fully Human Antibody Discovery Platform
Tuesday, November 15:
Oral Presentation: Innovative Bispecific Therapeutic Antibody Discovery with the RenLite Fully Human Common Light Chain Antibody Platform
Poster B6：YH013, a Fully-Human EGFR x MET Bispecific ADC Exhibits Outstanding Specificity and Anti-Tumor Efficacy
Biocytogen welcomes licensing and co-development inquiries. Interested parties may contact us at [email protected] to set up a meeting.
Click here to read the abstract of our oral presentation and view the conference schedule.
Click here to view the complete schedule for poster presentations.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen’s pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
